@ChaunceyGardner 1/10. Several clinical trials have shown that the mean nasal mucociliary clearance is negatively and significantly affected by cigarette smoking (PMIDs: 24669080, 3787531, 23615315, medrxiv.org/content/10.110…).
@ChaunceyGardner 2/10. Ciliary beat frequency is also significantly affected by smoking habit. A reduced nasal ciliary beat frequency was observed among smoking individuals in a cohort study performed in a British urban population (PMID: 9669071).
@ChaunceyGardner 3/10. In vitro, using human 3D epithelial cultures, cigarette smoke affects the cilia beat frequency in nasal and bronchial tissue cultures (PMIDs: 33220401, 30090531). In vivo, smoke exposure also affects cilia beat frequency in mice (PMID: 20042711).
@ChaunceyGardner 4/10. Given the consistency of these observations, and the dose response (e.g. PMID: 23615315), these mucociliary clearance-related endpoints are translational between human clinical, human in vitro and in vivo animal studies.
@ChaunceyGardner 5/10. Smoking cessation leads to an improvement of mucociliary clearance (PMIDs: 21545372, 24863424, medrxiv.org/content/10.110…). Hence, the cilia function recovers over time following smoking cessation (as you wrote in your Tweet).
@ChaunceyGardner 6/10. Now, the important question: How does switching to a heated tobacco product or an e-vapor product affect mucociliary clearance and cilia function?
@ChaunceyGardner 7/10. In vitro, these product aerosols do not significantly affect cilia function (PMIDs: 33220401, 30090531).
@ChaunceyGardner 8/10. In humans, switching to these products leads to an improvement of mucociliary clearance similar to that following smoking cessation (medrxiv.org/content/10.110…).
@ChaunceyGardner 9/10. Why is this important? Impaired mucociliary clearance predisposes COPD patients to exacerbations (PMIDs: 32640859, 25389352), and cessation reduces the number of these exacerbations.
@ChaunceyGardner 10/10. Similar to cessation, switching to an e-vapor (PMID: 33101622) or heated tobacco product (doi.org/10.1101/2020.1…; savvysciencepublisher.com/downloads/gjrc…) reduces the number of exacerbations and improves the patients’ CAT score.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Manuel Peitsch

Manuel Peitsch Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ManuelPeitsch

15 Mar 19
@Clive_Bates @PMIScience 1/10. First, let’s be cautious about over interpretation of single studies. As always, the quantification of harm/risk reduction in humans cannot be derived from any single study, but needs an analysis of the totality of the evidence for a given product.
@Clive_Bates @PMIScience 2/10. Second, definitive quantification of harm/risk reduction will come from population-level studies, including epidemiology, that take into account product use behaviors.
@Clive_Bates @PMIScience 3/10. Nevertheless, this in vivo study provides some insights into this legitimate question. Let’s consider the following background facts and observations:
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!